BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance
January 11 2022 - 6:00AM
BioRestorative Therapies, Inc. (the “Company" or “BioRestorative”)
(NASDAQ:BRTX
), a life sciences company focused on
stem cell-based therapies, today announced that Robert Paccasassi
has been appointed Vice President of Quality Assurance/Regulatory
Compliance. Mr. Paccasassi will lead quality initiatives through
the next phase of the Company’s growth as patient enrollment is
initiated for the Phase 2 clinical trial to treat chronic lumbar
disc disease.
Mr. Paccasassi has over 25 years of biotech
operations and combined experience in Quality Assurance, Regulatory
Compliance, and Manufacturing. Prior to joining BioRestorative, Mr.
Paccasassi held the role of Director, Corporate Quality Systems
(GMP) at Merck KGaA (Germany). Additionally, he also held Quality
and Compliance roles at Regeneron Pharmaceuticals, Millennium
Pharmaceuticals and Biogen Idec.. Mr. Paccasassi received his B.S.
in Medical Technology/Biology from the University of Rhode Island
and an MBA from Johnson and Wales University.
Mr. Paccasassi will be responsible for
BioRestorative’s cGMP Quality Control and Regulatory Compliance
operations as they relate to the Company’s product pipeline.
“We are fortunate to have Bob in a leadership
role overseeing our quality and compliance activities.” said Lance
Alstodt, CEO of BioRestorative. “Bob brings a great deal of
expertise to the organization, providing capabilities and
discipline to our already strong quality systems.”
About BioRestorative Therapies, Inc.
BioRestorative Therapies, Inc.
(www.biorestorative.com) develops therapeutic products using cell
and tissue protocols, primarily involving adult stem cells. Our two
core programs, as described below, relate to the treatment of
disc/spine disease and metabolic disorders:
• Disc/Spine Program (brtxDISC™): Our lead cell
therapy candidate, BRTX-100, is a product formulated from
autologous (or a person’s own) cultured mesenchymal stem cells
collected from the patient’s bone marrow. We intend that the
product will be used for the non-surgical treatment of painful
lumbosacral disc disorders or as a complementary therapeutic to a
surgical procedure. The BRTX-100 production process
utilizes proprietary technology and involves collecting a patient’s
bone marrow, isolating and culturing stem cells from the bone
marrow and cryopreserving the cells. In an outpatient
procedure, BRTX-100 is to be injected by a physician into
the patient’s damaged disc. The treatment is intended for patients
whose pain has not been alleviated by non-invasive procedures and
who potentially face the prospect of surgery. We have received
authorization from the Food and Drug Administration to commence a
Phase 2 clinical trial using BRTX-100 to treat chronic
lower back pain arising from degenerative disc disease.
• Metabolic Program (ThermoStem®): We are
developing a cell-based therapy candidate to target obesity and
metabolic disorders using brown adipose (fat) derived stem cells to
generate brown adipose tissue (“BAT”). BAT is intended to mimic
naturally occurring brown adipose depots that regulate metabolic
homeostasis in humans. Initial preclinical research indicates that
increased amounts of brown fat in animals may be responsible for
additional caloric burning as well as reduced glucose and lipid
levels. Researchers have found that people with higher levels of
brown fat may have a reduced risk for obesity and
diabetes.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. You are cautioned that such
statements are subject to a multitude of risks and uncertainties
that could cause future circumstances, events or results to differ
materially from those projected in the forward-looking statements
as a result of various factors and other risks, including, without
limitation, those set forth in the Company's latest Form 10-K filed
with the Securities and Exchange Commission. You should consider
these factors in evaluating the forward-looking statements included
herein, and not place undue reliance on such statements. The
forward-looking statements in this release are made as of the date
hereof and the Company undertakes no obligation to update such
statements.
CONTACT:
Email: ir@biorestorative.com
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Jun 2024 to Jul 2024
BioRestorative Therapies (NASDAQ:BRTX)
Historical Stock Chart
From Jul 2023 to Jul 2024